PRNP and neoplasm: If the in silico observation of increased expression of PrPC in cancer cells under optimal conditions does not modulate proliferation, resistance to cell death, and metabolism can be independently confirmed by in vitro/in vivo studies, then the concept of melatonin as a “broad-based metabolic buffer” characterized by exceptional antioxidant-dependent and -independent features that can fine-tune the tumor microenvironment at appropriate or even continuous applications may be an additional, but perhaps essential, consideration as a viable therapeutic solution to counter cancer MDR.